Aim: The most effective treatment for patients with chronic hepatitis C virus infection is pegylated interferon (PegIFNa) and Ribavirin combination therapy. The aim of this study was to examine the effect of PegIFN and Ribavirin combination therapy in patients infected with hepatitis C virus, using the application Microsoft SQL Server. Material and Method: We compared the rates of sustained virological response, who is defined as the absence of HCV RNA in serum 24 weeks after the end of treatment, between patients with different genotype (1,2,3 and 4), gender (male and female) and age (patients aged 19-45 years and patients aged ≥45 years). Results: The majority of patients were male patients (n= 173) and only 24% (n= 47) were female patients. The number of genotype 1 and 2 patients was 80(34.7%) and 14(6.1%), respectively, and the number of genotype 3 and 4 was 108(46.9%) and 28(12.3%). SVR rates in the patients according with their HCV genotype were 48.3%(n= 25) for genotype 1, 50%(n= 5) for genotype 2, for genotype 3 were 61.5%(n= 43) and for genotype 4 were 19.1%(n= 4). Conclusions: In conclusion, this study show that the efficacy of PegIFN and Ribavirin combination therapy for HCV infection in patients with genotype 2 or 3 , in female patients and in patients aged 19-45 years is superior to those in genotype 1and 4, male patients and patients aged ≥ 45 years. The use of Microsoft SQL Server was efficient, simple, safe, not time consuming and precise. This software can be used for optimal efficiency in the process of medical analysis and reviews.


Chronic hepatitis C, Database, Software, Efficacity of treatment